| Literature DB >> 28445408 |
Stephen Bleakley1,2, Maria Hayes3.
Abstract
Population growth combined with increasingly limited resources of arable land and fresh water has resulted in a need for alternative protein sources. Macroalgae (seaweed) and microalgae are examples of under-exploited "crops". Algae do not compete with traditional food crops for space and resources. This review details the characteristics of commonly consumed algae, as well as their potential for use as a protein source based on their protein quality, amino acid composition, and digestibility. Protein extraction methods applied to algae to date, including enzymatic hydrolysis, physical processes, and chemical extraction and novel methods such as ultrasound-assisted extraction, pulsed electric field, and microwave-assisted extraction are discussed. Moreover, existing protein enrichment methods used in the dairy industry and the potential of these methods to generate high value ingredients from algae, such as bioactive peptides and functional ingredients are discussed. Applications of algae in human nutrition, animal feed, and aquaculture are examined.Entities:
Keywords: bioavailability; biorefinery; extraction methods; legislation; microalgae; peptides; phycobiliproteins; seaweed
Year: 2017 PMID: 28445408 PMCID: PMC5447909 DOI: 10.3390/foods6050033
Source DB: PubMed Journal: Foods ISSN: 2304-8158
Figure 1Schematic representation of digestion and methods that may be used to determine bioavailability, bio-accessibility and bioactivity of proteins and other foods. Adapted from Carbonell-Capella et al. [47]. TIM: TNOASR’s intestinal model; TNOASR: The Netherlands Organization for Applied Scientific Research.
Conventional pre-treatment cell disruption methods and extraction methods for precipitating proteins from seaweed. Dry weight; dw.
| Extraction Method | Species | Extraction Name | Reagents | Protein Yield | Reference |
|---|---|---|---|---|---|
| Enzymatic hydrolysis | Polysaccharidase degradation | Cellulase (Cellucast®) and xylanase (Shearzyme®) | Factor 3.3 compared to control | [ | |
| Polysaccharidase degradation | κ-carrageenase, β-agarase, xylanase, cellulase | - | [ | ||
| Polysaccharidase degradation | Cellulase (Cellucast®), xylanase (Shearzyme®) and Ultraflo® (β-glucanase) | 11.57 ± 0.08 g/100 g dw (67% yield) | [ | ||
| Physical Process | Aqueous treatment and Potter homogenisation | Ultra-pure water | 8.9 g/100 g dw, | [ | |
| Osmotic stress | - | 6.77 ± 0.22 g/100 g dw (39% yield) | [ | ||
| High shear force | - | 6.92 ± 0.12 g/100 g dw (40% yield) | |||
| Chemical extraction | Acid-alkaline treatment | 0.4 M HCl and 0.4 M NaOH | 59.76% yield | [ | |
| Two-phase system | NaOH and 2-mercaptoethanol | - | [ | ||
| Two-phase system | Polyethylene glycol (PEG) and potassium carbonate | - | [ | ||
| Alkaline and aqueous | NaOH and N-acetyl-
| 4.16 g/100 g dw (24% yield) | [ |
Angiotensin-I-converting enzyme (ACE)-I inhibitory bioactive peptides derived from seaweed and microalgae. The potency of the peptides is indicated by their IC50 values, which refers to the concentration required to inhibit enzyme activity by 50%.
| Source | Hydrolytic Method | Peptide Sequence | IC50 | Reference |
|---|---|---|---|---|
| Pepsin | Ala-Ile-Tyr-Lys | 213 μM | [ | |
| Tyr-Lys-Tyr-Tyr | 64.2 μM | |||
| Lys-Phe-Tyr-Gly | 90.5 μM | |||
| Tyr-Asn-Lys-Leu | 90.5 μM | |||
| Hot water extraction | Tyr-His | 5.1 μM | [ | |
| Lys-Trp | 10.8 μM | |||
| Lys-Tyr | 7.7 μM | |||
| Lys-Phe | 28.3 μM | |||
| Phe-Tyr | 3.7 μM | |||
| Val-Trp | 10.8 μM | |||
| Val-Phe | 43.7 μM | |||
| Ile-Tyr | 2.7 μM | |||
| Ile-Trp | 12.4 μM | |||
| Val-Tyr | 11.3 μM | |||
| Protease S “Amano” | Val-Tyr | 35.2 μM | [ | |
| Ile-Tyr | 6.1 μM | |||
| Ala-Trp | 18.8 μM | |||
| Phe-Tyr | 42.3 μM | |||
| Val-Trp | 3.3 μM | |||
| Ile-Trp | 1.5 μM | |||
| Leu-Trp | 23.6 μM | |||
| Alcalase | Enzymatic digest | 2.79 μg/mL | [ | |
| Flavourzyme | Enzymatic digest | 3.56 μg/mL | ||
| Kojizyme | Enzymatic digest | 2.33 μg/mL | ||
| Neutrase | Enzymatic digest | 3.10 μg/mL | ||
| Protamex | Enzymatic digest | 3.28 μg/mL | ||
| Ile-Tyr | 2.69 μM | [ | ||
| Met-Lys-Tyr | 7.26 μM | |||
| Ala-Lys-Tyr-Ser-Tyr | 1.52 μM | |||
| Leu-Arg-Tyr | 5.06 μM | |||
| Gly-Lys-Tyr | 3.92 μM | [ | ||
| Ser-Val-Tyr | 8.12 μM | |||
| Ser-Lys-Thr-Tyr | 11.07 μM | |||
| Thermolysin | Val-Tyr-Arg-Thr | 0.14 μM | [ | |
| Leu-Asp-Tyr | 6.1 μM | |||
| Leu-Arg-Tyr | 0.044 μM | |||
| Phe-Glu-Gln-Trp-Ala-Ser | 2.8 μM | |||
| Pepsin | Ile-Val-Val-Glu | 315.3 μM | [ | |
| Ala-Phe-Leu | 63.8 μM | |||
| Phe-Ala-Leu | 26.3 μM | |||
| Ala-Glu-Leu | 57.1 μM | |||
| Val-Val-Pro-Pro-Ala | 79.5 μM | |||
| Ile-Ala-Glu | 34.7 μM | |||
| Phe-Ala-Leu | 11.4 μM | |||
| Ala-Glu-Leu | 11.4 μM | |||
| Ile-Ala-Pro-Gly | 11.4 μM | |||
| Val-Ala-Phe | 35.8 μM | |||
| Alcalase | Leu-Val-Thr-Val-Met | 18.0 μM | [ | |
| Pepsin | Gly-Met-Asn-Asn-Leu-Thr-Pro | 123 μM | [ | |
| Leu-Glu-Gln | 173 μM | |||
| Protamex, Kojizyme, Neutrase, Flavourzyme, Alcalase, trypsin, α-chymotrypsin, pepsin, and papain | Val-Glu-Gly-Tyr | 128.4 μM | [ | |
| Flavourzyme, alcalase, papain, and pepsin | Val-Glu-Cys-Tyr-Gly-Pro-Asn-Arg-Pro-Gln-Phe | 29.6 μM | [ |
Figure 2Schematic representation of the renin–angiotensin–aldosterone system (RAAS) and the hypertensive effect of angiotensin-I-converting enzyme (ACE-I). Angiotensinogen is converted to the decapeptide angiotensin-I by renin. ACE-I cleaves the C-terminal dipeptide His-Leu of angiotensin-I to form angiotensin-II. Binding of angiotensin-II to its receptor (AT1) stimulates the secretion of inositol 1,4,5-triphosphate (IP3) and aldosterone, which induce arteriolar vasoconstriction and increased intravascular fluid volume, respectively, resulting in increased blood pressure. Within the kallikrein–kinin system, kallikrein converts kininogen to bradykinin, which induces arteriolar vasodilation by prostaglandin secretion and binding of bradykinin with its receptor, resulting in decreased blood pressure. However, the hypotensive effect of bradykinin is largely dependent on the rate of degradation by ACE-I, which hydrolyzes bradykinin to form inactive metabolites.